Benzinga

Benzinga

Benzinga

sábado, agosto 29

ADC Therapeutics SA

ADCTNYSE
Trade with Public
Trade with Public
$1.14
0.021.79%
al cierre: Aug 28, 5:00 PM EST
$1.12
-0.0198-1.74%
After hour: 7:21 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

ADC Therapeutics Financials

ADC Therapeutics (ADCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the
Benzinga Newsdesk

PRO
ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the
Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

ADC Therapeutics: Q4 Earnings Insights

Benzinga Insights

PRO
ADC Therapeutics Q4 Adj. EPS $(0.09) Beats $(0.27) Estimate, Sales $23.058M Beat $21.390M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.27) by 66.42 percent. This is a 64 percent increase over losses of $(0.25) per share from the
Benzinga Newsdesk

Earnings Scheduled For March 10, 2026

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved